KB:NYSEKB Financial Group Inc Analysis
Data as of 2026-06-21 - not real-time
$106.77
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
KB Financial Group trades at $106.77, comfortably above its 20‑day SMA of 105.08 and just above the 50‑day SMA of 106.61, indicating short‑term momentum. The RSI of 51.3 suggests the stock is neither overbought nor oversold, while a bullish MACD (histogram 0.64) reinforces the upward bias. Price sits midway between a support level of 99.35 and resistance near 115.85, leaving roughly 9% upside to the next resistance band.
Fundamentally, KB appears undervalued with a trailing PE of 10.1 versus an industry average of 16.9, and a forward PE of 8.7. Revenue is expanding at a healthy 15.2% YoY, and the dividend yield of 2.94% is supported by a modest payout ratio of 27%. However, the stock exhibits high 30‑day volatility (≈ 43.6%) and a computed beta of 1.38**, signaling sensitivity to market swings. Overall, the blend of attractive valuation, solid earnings growth, and a sustainable dividend makes KB a compelling candidate for investors willing to tolerate moderate risk.
Fundamentally, KB appears undervalued with a trailing PE of 10.1 versus an industry average of 16.9, and a forward PE of 8.7. Revenue is expanding at a healthy 15.2% YoY, and the dividend yield of 2.94% is supported by a modest payout ratio of 27%. However, the stock exhibits high 30‑day volatility (≈ 43.6%) and a computed beta of 1.38**, signaling sensitivity to market swings. Overall, the blend of attractive valuation, solid earnings growth, and a sustainable dividend makes KB a compelling candidate for investors willing to tolerate moderate risk.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price above short‑term moving averages
- Bullish MACD but neutral overall trend
- Support level provides downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued relative to industry PE
- Strong revenue growth and sustainable dividend
- Increasing volume indicating growing investor interest
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Attractive valuation multiples and forward PE
- Consistent dividend yield with low payout ratio
- Diversified product suite across multiple geographies
Key Metrics & Analysis
Financial Health
Revenue Growth15.20%
Profit Margin36.58%
P/E Ratio10.1
ROE9.99%
ROA0.76%
P/B Ratio4.1
Op. Cash Flow$-26548566491136
Industry P/E16.9
Technical Analysis
TrendNeutral
RSI51.3
Support$99.35
Resistance$115.85
MA 20$105.08
MA 50$106.61
MA 200$95.01
MACDBullish
VolumeIncreasing
Fear & Greed Index91.46
Valuation
Target Price$127.42
Upside/Downside19.34%
GradeUndervalued
TypeBlend
Dividend Yield2.94%
Risk Assessment
Beta1.38
Volatility43.58%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.